GlassScriptPhysician profile
Michael T Caglia
NPI 1568789550
$222,115.64
in general payments reported to CMS, 2019-2025
32 companies · $1,925 in 2025
The $1,925 reported for 2025 was more than what 75% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $87K · 2020: $64K · 2021: $57K · 2022: $7,701 · 2023: $2,625 · 2024: $2,104 · 2025: $1,925.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,545 · Education: $109.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,544.70 |
| Education | $108.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $69,439.61 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $60,407.77 | 2019-2025 | Ilumya |
| Celgene Corporation | $47,373.14 | 2019 | |
| Amgen INC. | $34,018.69 | 2020-2025 | Otezla, Enbrel, Otezla |
| Abbvie INC. | $2,367.08 | 2019-2025 | Botox, Skyrizi, Rinvoq |
| Novartis Pharmaceuticals Corporation | $1,230.21 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $1,007.69 | 2021-2025 | Sotyktu |
| Mayne Pharma Commercial LLC | $1,003.10 | 2019-2025 | |
| Incyte Corporation | $751.08 | 2021-2025 | Opzelura |
| Arcutis Biotherapeutics, INC. | $641.76 | 2023-2025 | Zoryve |
| Regeneron Healthcare Solutions, INC. | $550.98 | 2019-2025 | Dupixent, Libtayo |
| Janssen Biotech, INC. | $469.85 | 2019-2025 | Tremfya, Simponi Aria, Stelara |
| Ucb, INC. | $446.06 | 2020-2025 | Bimzelx, Cimzia |
| Dermavant Sciences, INC. | $355.85 | 2022-2024 | Vtama |
| Lilly USA, LLC | $354.00 | 2019-2025 | Taltz, Olumiant, Ebglyss |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Journey Medical Corporation | $258.10 | 2022-2025 | |
| Leo Pharma INC. | $241.72 | 2022-2025 | Adbry |
| Pfizer INC. | $205.32 | 2019-2023 | |
| Genzyme Corporation | $188.26 | 2024 | |
| Organon LLC | $122.77 | 2025 | Vtama |
| Allergan, INC. | $121.21 | 2021-2022 | |
| Galderma Laboratories, L.P. | $118.69 | 2019-2022 | |
| Biofrontera INC. | $104.05 | 2019-2023 | Ameluz, Xepi, Bf-Rhodoled |
| Boehringer Ingelheim Pharmaceuticals, INC. | $82.72 | 2022-2025 | Spevigo, Cyltezo |
| Almirall LLC | $62.26 | 2019-2022 | |
| Genentech USA, INC. | $50.09 | 2019-2022 | |
| Tactile Systems Technology INC | $47.56 | 2024 | Entre Plus, Flexitouch Plus |
| Kyowa Kirin, INC. | $23.50 | 2025 | |
| Dusa Pharmaceuticals, INC. | $20.21 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $19.97 | 2020 | |
| Dermira, INC. | $18.43 | 2020 | |
| Merck Sharp & Dohme LLC | $13.91 | 2023 | Keytruda |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Caglia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.